Eosinophil Peroxidase: A Biomarker for Eosinophilic Chronic Rhinosinusitis Agnostic of Polyp Status.
IL-5
biomarker
chronic rhinosinusitis
eosinophil peroxidase
eosinophilia
interleukin 5
nasal polyps
sinusitis
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
revised:
03
05
2023
received:
22
12
2022
accepted:
15
05
2023
pmc-release:
30
11
2024
medline:
31
5
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
aheadofprint
Résumé
To evaluate eosinophil peroxidase (EPX) as a biomarker for tissue levels of eosinophilia, cytokines, and chemokines within chronic rhinosinusitis (CRS). Twenty-eight subjects undergoing sinonasal surgery were prospectively enrolled. Ethmoid tissue was analyzed with an in-house EPX immunoassay and a 48-plex cytokine-chemokine array. Clinical severity was assessed using SNOT-22 and Lund-Mackay scores. Subjects were grouped as follows: controls, polyp status (CRS with [CRSwNP] and without nasal polyps [CRSsNP]), tissue eosinophilia (eosinophilic CRS [eCRS], non-eosinophilic CRS [neCRS]), or combinations thereof (eCRSwNP, eCRSsNP, neCRSsNP). eCRS was defined as >10 eosinophils per high power field (HPF). Subjects without CRS or asthma were enrolled as controls. EPX was elevated in CRSwNP compared to control (p = 0.007), in eCRS compared to neCRS (p = 0.002), and in eCRSwNP along with eCRSsNP compared to neCRSsNP (p = 0.023, p = 0.015, respectively). eCRS displayed elevated IL-5 compared to neCRS (p = 0.005). No significant differences in EPX or IL-5 were observed between eCRSwNP and eCRSsNP. IL-5 was elevated in eCRSwNP (p = 0.019) compared neCRSsNP. Area under the receiver operator characteristic curve was 0.938 (95% CI, 0.835-1.00) for EPX and tissue eosinophilia, with an optimal cut-point of 470 ng/mL being 100% specific and 81.25% sensitive for tissue eosinophilia. Linear regression revealed a strong correlation between EPX and IL-5 (R EPX is associated with tissue eosinophilia in CRS patients regardless of polyp status. EPX correlates with IL-5 and could be potentially considered a biomarker for anti-IL-5 therapies. 3 Laryngoscope, 2023.
Identifiants
pubmed: 37255054
doi: 10.1002/lary.30787
pmc: PMC10687314
mid: NIHMS1903153
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R37 AI071106
Pays : United States
Informations de copyright
© 2023 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Allergy. 2016 Apr;71(4):567-70
pubmed: 26645423
J Exp Med. 2019 May 6;216(5):1170-1181
pubmed: 30910796
Int Immunol. 2019 Feb 6;31(1):33-40
pubmed: 30239772
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2812-2820.e3
pubmed: 31128376
Allergy Asthma Immunol Res. 2021 Jan;13(1):8-22
pubmed: 33191674
Int Forum Allergy Rhinol. 2021 Aug;11(8):1207-1219
pubmed: 33611865
Am J Rhinol Allergy. 2018 Jul;32(4):252-257
pubmed: 29862828
Rhinology. 2021 Aug 1;59(4):330-339
pubmed: 34350429
Int Forum Allergy Rhinol. 2017 Oct;7(10):957-962
pubmed: 28742240
Int Forum Allergy Rhinol. 2018 May;8(5):592-604
pubmed: 29337425
J Allergy Clin Immunol. 2005 Aug;116(2):362-9
pubmed: 16083791
Int Forum Allergy Rhinol. 2018 Dec;8(12):1421-1429
pubmed: 30091850
J Biol Chem. 1998 Jan 16;273(3):1764-8
pubmed: 9430724
Int Forum Allergy Rhinol. 2019 Apr;9(4):402-408
pubmed: 30570840
Clin Immunol. 2007 Dec;125(3):291-8
pubmed: 17911044
Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739
pubmed: 33236525
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
J Allergy Clin Immunol. 2016 May;137(5):1449-1456.e4
pubmed: 26949058
J Leukoc Biol. 1998 Jun;63(6):715-22
pubmed: 9620664
Am J Clin Pathol. 1981 May;75(5):693-700
pubmed: 7234755
Ann Allergy Asthma Immunol. 2022 Aug;129(2):160-168
pubmed: 35398492
J Leukoc Biol. 2003 Mar;73(3):356-62
pubmed: 12629149
J Leukoc Biol. 2000 Sep;68(3):400-4
pubmed: 10985257
Clin Exp Immunol. 2002 Feb;127(2):270-3
pubmed: 11876749
PLoS One. 2010 Jul 06;5(7):e11450
pubmed: 20625511
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1454-1461
pubmed: 35231626
Thorax. 2002 May;57(5):449-51
pubmed: 11978925
Allergy. 2021 Nov;76(11):3349-3358
pubmed: 33948955
Curr Opin Allergy Clin Immunol. 2020 Feb;20(1):23-29
pubmed: 31688152
J Immunol Methods. 2012 Oct 31;384(1-2):10-20
pubmed: 22750539
Sci Rep. 2016 May 24;6:26604
pubmed: 27216292
J Clin Invest. 2018 Mar 1;128(3):997-1009
pubmed: 29400693
Int Forum Allergy Rhinol. 2021 Jan;11(1):8-15
pubmed: 32472743
Front Immunol. 2022 Jul 07;13:938691
pubmed: 35874692
J Allergy Clin Immunol. 2019 Jun;143(6):2284-2287.e6
pubmed: 30738839
J Allergy Clin Immunol. 2021 Apr;147(4):1306-1317
pubmed: 33326802
Otolaryngol Head Neck Surg. 2010 Jan;142(1):64-71
pubmed: 20096225
J Allergy Clin Immunol. 2022 Jul;150(1):22-32
pubmed: 35469844
J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1
pubmed: 25282015
Curr Allergy Asthma Rep. 2020 Apr 22;20(6):16
pubmed: 32323067
J Otolaryngol Head Neck Surg. 2019 May 29;48(1):23
pubmed: 31142355
Int Forum Allergy Rhinol. 2018 Jul;8(7):797-805
pubmed: 29437297
Allergy. 2018 Jul;73(7):1459-1469
pubmed: 29331025
J Allergy Clin Immunol. 2017 Dec;140(6):1705-1708.e3
pubmed: 28870464
Otolaryngol Head Neck Surg. 2015 Apr;152(2 Suppl):S1-S39
pubmed: 25832968
Am J Respir Cell Mol Biol. 1999 Sep;21(3):291-5
pubmed: 10460744
J Immunol. 2006 Nov 15;177(10):7340-5
pubmed: 17082653
Crit Rev Immunol. 2002;22(2):105-14
pubmed: 12433129
Int Forum Allergy Rhinol. 2012 Sep-Oct;2(5):376-85
pubmed: 22419386
Int Forum Allergy Rhinol. 2017 Apr;7(4):373-379
pubmed: 28042687